PMID- 26865364
OWN - NLM
STAT- MEDLINE
DCOM- 20160916
LR  - 20220330
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 16
DP  - 2016 Feb 11
TI  - Protective effect of Sheng-Mai Yin, a traditional Chinese preparation, against 
      doxorubicin-induced cardiac toxicity in rats.
PG  - 61
LID - 10.1186/s12906-016-1037-9 [doi]
LID - 61
AB  - BACKGROUND: Sheng-Mai Yin (SMY), a modern Chinese formula based on Traditional 
      Chinese Medicine theory, has been used to treat cardiovascular diseases in 
      Eastern Asia. Our study focuses on the cardioprotection of SMY against 
      doxorubicin (DOX)-induced cardiac toxicity in vivo. METHODS: Rats were injected 
      with DOX (2.5 mg/kg) in six injections over a 2-week period. SMY was 
      administrated intragastrically at the dose of 8.35, 16.7 and 33.4 g/kg, or 16.7 
      g/kg only twice a day concurrently with DOX for the 2-weeks. A series of assays 
      were performed to detect the effects of SMY on: (i) heart weight index (HWI) and 
      left ventricular mass index (LVMI); (ii) cardiac function; (iii) heart tissue 
      morphology; (iv) the contents of carboxy terminal propeptide of procollagen typeI 
      (PICP), amino terminal propeptide of procollagen type III (Pcapital SHA, CyrillicNP), transforming 
      growth factor-beta1 (TGF-beta1), B-type natriuretic peptide (BNP), monocyte 
      chemoattractant protein-1 (MCP-1), interferon gamma (INF-gamma) and interleukin 6 
      (IL-6) by ELISA; (v) the mRNA levels of TGF-beta1 and toll-like receptor-2 (TLR2); 
      and (vi) protein level of TGF-beta1. RESULTS: Rats treated with SMY displayed the 
      reductions of BNP and CK-MB increased by DOX in a dose-dependent manner. Moderate 
      dose of SMY exhibited the correction for the increased HWI, LVMI, and the injured 
      cardiac function, as well as the collagen accumulation. In addition, 
      cardioprotection of SMY against DOX-induced cardiac toxicity was demonstrated by 
      the reduction of myocardial fibrosis, characterized by the suppression of PICP, 
      Pcapital SHA, CyrillicNP and TGF-beta1, as well as the anti-inflammation and the regulation for cardiac 
      immune microenvironment, characterized by the inhibition of TLR2, MCP-1, INF-gamma 
      and IL-6. CONCLUSIONS: SMY may protect heart function through the restriction of 
      myocardial fibrosis induced by DOX, which suggests the potentially therapeutic 
      effect of SMY on DOX-induced cardiomyopathy.
FAU - Ma, Shaojun
AU  - Ma S
AD  - Department of Oncology, Tianjin Nankai Hospital, 122 San Wei Lu, Nan Kai 
      District, Tianjin, 300100, China.
FAU - Li, Xiaojiang
AU  - Li X
AD  - Department of Oncology, The First Affiliated Hospital to Tianjin University of 
      Traditional Chinese Medicine, 314 An Shan Xi Dao, Nan Kai District, Tianjin, 
      300193, China.
FAU - Dong, Liang
AU  - Dong L
AD  - Department of Oncology, The First Affiliated Hospital to Tianjin University of 
      Traditional Chinese Medicine, 314 An Shan Xi Dao, Nan Kai District, Tianjin, 
      300193, China.
FAU - Zhu, Jinli
AU  - Zhu J
AD  - Department of Oncology, The First Affiliated Hospital to Tianjin University of 
      Traditional Chinese Medicine, 314 An Shan Xi Dao, Nan Kai District, Tianjin, 
      300193, China.
FAU - Zhang, He
AU  - Zhang H
AD  - Department of Oncology, Tianjin Nankai Hospital, 122 San Wei Lu, Nan Kai 
      District, Tianjin, 300100, China.
FAU - Jia, Yingjie
AU  - Jia Y
AD  - Department of Oncology, The First Affiliated Hospital to Tianjin University of 
      Traditional Chinese Medicine, 314 An Shan Xi Dao, Nan Kai District, Tianjin, 
      300193, China. jiayjjiayj@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160211
PL  - England
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Inflammation Mediators)
RN  - 0 (fructus schizandrae, radix ginseng, radix ophiopogonis drug combination)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 80168379AG (Doxorubicin)
RN  - EC 2.7.3.2 (Creatine Kinase, MB Form)
SB  - IM
MH  - Animals
MH  - Cardiomyopathies/*prevention & control
MH  - Cardiotonic Agents/*therapeutic use
MH  - Cardiotoxicity/*prevention & control
MH  - Creatine Kinase, MB Form/blood
MH  - Disease Models, Animal
MH  - Doxorubicin/*adverse effects/antagonists & inhibitors
MH  - Drug Combinations
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Heart/drug effects
MH  - Inflammation Mediators/blood
MH  - Male
MH  - Natriuretic Peptide, Brain/blood
MH  - Organ Size/drug effects
MH  - Rats
MH  - Rats, Wistar
PMC - PMC4750239
EDAT- 2016/02/13 06:00
MHDA- 2016/09/17 06:00
PMCR- 2016/02/11
CRDT- 2016/02/12 06:00
PHST- 2015/07/28 00:00 [received]
PHST- 2016/02/03 00:00 [accepted]
PHST- 2016/02/12 06:00 [entrez]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2016/09/17 06:00 [medline]
PHST- 2016/02/11 00:00 [pmc-release]
AID - 10.1186/s12906-016-1037-9 [pii]
AID - 1037 [pii]
AID - 10.1186/s12906-016-1037-9 [doi]
PST - epublish
SO  - BMC Complement Altern Med. 2016 Feb 11;16:61. doi: 10.1186/s12906-016-1037-9.